Supplementary Figure S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

作者：Yihebali Chi, Xiangqian Zheng, Yuan Zhang, Feng Shi, Ying Cheng, Zhuming Guo, Minghua Ge, Jianwu Qin, Jiewu Zhang, Zhendong Li, Xiaohong Zhou, Rui Huang, Xiaohong Chen, Hui Liu, Ruochuan Cheng, Zhengang Xu, Dapeng Li, Pingzhang Tang, Ming Gao · 年份：2025 · DOI：10.1158/1078-0432.30710302 · 研究领域：Thyroid Cancer Diagnosis and Treatment、Lung Cancer Research Studies、Neuroendocrine Tumor Research Advances

<p>(A) Kaplan–Meier estimate of progress-free survival (PFS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease beyond 3 months before enrollment. (C) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease within 12 months before enrollment. (D) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease beyond 12 months before enrollment. The tick marks indicate censored data.</p>